$1.70 +0.03 (1.80%) Curis Inc - NASDAQ

Aug. 25, 2016 | 04:00 PM
Last Trade: 1.70
Trade Time: Aug 25 04:00 PM Eastern Daylight Time
Change: +0.03 (1.80%)
Prev Close: 1.67
Open: 1.67
Bid: 1.70
Ask: 1.71
  1. No results found.
  1. Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at #ASH2015

    Benzinga | Dec. 6, 2015 | 19:14PM EST
  2. Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC Conference

    Benzinga | Nov. 8, 2015 | 16:58PM EST
  3. Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

    Benzinga | Nov. 5, 2015 | 09:25AM EST
  4. Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

    Benzinga | May. 20, 2015 | 07:01AM EST
  5. Friday's After-Hours Movers: Etsy, Cliffs Natural Resources And More

    Benzinga | Apr. 17, 2015 | 18:08PM EST
  6. UPDATE: Oppenheimer Raises Price Target On Curis On Aurigene Collaboration

    Benzinga | Jan. 22, 2015 | 09:45AM EST
  7. US Stock Futures Slip Ahead Of Housing-Starts Data

    Benzinga | Jan. 21, 2015 | 07:07AM EST
  8. Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors

    Benzinga | Dec. 18, 2014 | 07:26AM EST
  9. Events for the Week of Sept. 8-12

    Benzinga | Sep. 10, 2014 | 14:34PM EST
  10. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 18:25PM EST
  11. Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity

    Benzinga | Apr. 7, 2014 | 16:29PM EST
  12. Morning Market Movers

    Benzinga | Mar. 31, 2014 | 09:40AM EST
  13. UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies

    Benzinga | Dec. 6, 2013 | 09:37AM EST
  14. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 6, 2013 | 08:20AM EST
  15. Curis InitiatesRoche-Sponsored Phase 1b/2 Study of Erivedge in Relapsed/Refractory AML and High Risk MDS

    Benzinga | Oct. 4, 2013 | 07:02AM EST
Trading Center